Search ARWR
Arrowhead Pharmaceuticals, Inc.
NasdaqGS · CIK 879407
Last close64.19
Daily change-0.60 (-0.93%)
10 Years gain+794.01%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ARWR · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 0930
Fundamental
37.7Momentum
0.0Acceleration
0.0Confidence
87.0Annual Revenue15
Quarterly Revenue65
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth13.2 / 25
Quality5.7 / 25
Capital Efficiency4.9 / 20
Balance Sheet5.7 / 15
Shareholder Economics3.1 / 10
Forward Indicators5.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Negative FCF · HIGHLatest free cash flow is negative.
FCF deterioration · MEDIUMFree cash flow declined 649.1657%.
Operating margin compression · MEDIUMOperating margin compressed by 83.7951 percentage points.
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
Key Metrics
Revenue Growth TTM-19.15%OK
Revenue CAGR 3Y50.52%OK
Gross Margin100%OK
Operating Margin-98.93%OK
FCF Margin-55.63%OK
FCF Growth-649.17%OK
ROICn/aMISSING
Incremental Operating Margin 3Y-168.93%OK
Net Debt / CFO6.84xOK
Diluted Share Growth 1Y6.61%OK
SBC / Revenue14.51%OK
SBC / FCF-26.08%OK
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Sep 30, 2025 | $829.45M | $829.45M | $98.35M | $179.55M | $156.89M | 100% | 11.86% | 18.91% | n/a | 133.76M |
| 2025 FY Sep 30, 2024 | $3.55M | $3.55M | -$601.08M | -$462.85M | -$604.32M | 100% | -16,927.06% | -17,018.3% | n/a | 119.78M |
| 2025 FY Sep 30, 2023 | $240.74M | $240.74M | -$205.00M | -$153.89M | -$330.63M | 100% | -85.16% | -137.34% | -204.7% | 106.75M |
| 2024 FY Sep 30, 2022 | $243.23M | $243.23M | -$178.51M | -$136.13M | -$188.91M | 100% | -73.39% | -77.67% | -72.66% | 105.43M |
| 2023 FY Sep 30, 2021 | $138.29M | $138.29M | -$149.04M | $171.31M | $147.75M | 100% | -107.77% | 106.84% | -71.18% | 103.75M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $440.79M | sum latest 4 fiscal quarters Revenue | OK | 0000879407-26-000057, 0000879407-26-000034 |
| Revenue Growth TTM | -19.15% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000879407-26-000057, 0000879407-26-000034 |
| Revenue CAGR 3Y | 50.52% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000879407-25-000029 |
| Revenue CAGR 5Y | 56.63% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000879407-25-000029 |
| Gross Profit CAGR 3Y | 50.52% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000879407-25-000029 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0000879407-26-000057, 0000879407-26-000034 |
| FCF Growth | -649.17% | FCF_current / FCF_prior_year - 1 | OK | 0000879407-26-000057, 0000879407-26-000047 |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0000879407-26-000057, 0000879407-26-000034 |
| Operating Margin | -98.93% | Operating Income / Revenue | OK | 0000879407-26-000057, 0000879407-26-000034 |
| FCF Margin | -55.63% | (CFO - CapEx) / Revenue | OK | 0000879407-26-000057, 0000879407-26-000047 |
| Net Debt / CFO | 6.84x | Net Debt / CFO | OK | 0000879407-26-000057, 0000879407-26-000047 |
| Current Ratio | 5.9x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 14.51% | SBC / Revenue | OK | 0000879407-26-000057, 0000879407-26-000047 |
| Revenue per Diluted Share | $3.07 | Revenue / Diluted Shares | OK | 0000879407-26-000057, 0000879407-26-000034 |